ConductScience.org, home

Paper35599264

A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen.

Dayyani F and 6 others. Med Oncol, 2022. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. Papers, record 35599264. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35599264

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen.
PubMed
Journal
Med Oncol
PubMed
Year
2022
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Multicenter Study
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.1
iCite
Revised in PubMed
2023-05-24
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dayyani FFarshidhttps://orcid.org/0000-0002-4970-5189
2Tam KKit
3Kim EJEdward J
4Ejadi SSamuel
5Valerin JJennifer
6Taylor THThomas H
7Cho MTMay T

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenocarcinomaMajor topic
Esophageal NeoplasmsMajor topic
IrinotecanMajor topic
Stomach NeoplasmsMajor topic
Antineoplastic Combined Chemotherapy Protocols
Drug Combinations
Humans
Platinum
Pyrrolidines
Thymine
Trifluridine

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA062203NCI NIH HHSUnited StatesP30CA062203PubMed and NIHNIH RePORTER
P30 CA093373NCI NIH HHSUnited StatesP30CA093373PubMed and NIHNIH RePORTER

Download CSV of grants

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135202974
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.
Eur J Cancer2022https://conductscience.org/library/papers/35202974PubMed
227664260Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2016https://conductscience.org/library/papers/27664260PubMed
324078663Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2013https://conductscience.org/library/papers/24078663PubMed
433264544Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.N Engl J Med2020https://conductscience.org/library/papers/33264544PubMed
530234181Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.JCO Precis Oncol2018https://conductscience.org/library/papers/30234181PubMed
623192279
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Cancer Chemother Pharmacol2013https://conductscience.org/library/papers/23192279PubMed
732083013
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study.
Front Oncol2019https://conductscience.org/library/papers/32083013PubMed
825240821
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Lancet Oncol2014https://conductscience.org/library/papers/25240821PubMed
932901938Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk?J Surg Oncol2020https://conductscience.org/library/papers/32901938PubMed
1029543932Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.JAMA Oncol2018https://conductscience.org/library/papers/29543932PubMed
1125751757Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.Acta Oncol2015https://conductscience.org/library/papers/25751757PubMed
1224190112
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
J Clin Oncol2013https://conductscience.org/library/papers/24190112PubMed
1321573742Japanese gastric cancer treatment guidelines 2010 (ver. 3).Gastric Cancer2011https://conductscience.org/library/papers/21573742PubMed
1427795561A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.Leukemia2017https://conductscience.org/library/papers/27795561PubMed
1532612955Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.Front Oncol2020https://conductscience.org/library/papers/32612955PubMed
1632437664First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.Lancet Oncol2020https://conductscience.org/library/papers/32437664PubMed
1724094768Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet2014https://conductscience.org/library/papers/24094768PubMed
1824330513FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.J Exp Clin Cancer Res2013https://conductscience.org/library/papers/24330513PubMed
1930355453Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2018https://conductscience.org/library/papers/30355453PubMed
2020602191Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.Gastric Cancer2010https://conductscience.org/library/papers/20602191PubMed

See all 36 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
34175675Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.ESMO Open2021https://conductscience.org/library/papers/34175675

Source PubMed

Download CSV of cited by

Genes12

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35599264

GET https://conductscience.org/api/papers/v1/35599264/references?page=2